Metformin + saxagliptin for type 2 diabetes (Q37965618)

26 August 2017

title

Metformin + saxagliptin for type 2 diabetes (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

André J Scheen

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

139-146

1 reference

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Add-on therapies to metformin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642867

10.1517/14656566.2012.642867

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference